Peramivir Injection
Peramivir is an antiviral given by IV infusion to treat acute uncomplicated influenza (the flu) in patients 6 months and older.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Peramivir Injection: Patient Information Guide
A plain-language walkthrough of Peramivir Injection — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Rapivab (peramivir injection) is approved to treat acute uncomplicated influenza in patients 6 months and older.
- Rapivab treats acute uncomplicated influenza (flu) in adults, adolescents, and children 6 months of age and older
- Treatment must begin within 2 days of when flu symptoms start
- Clinical evidence is strongest for influenza A; effectiveness against influenza B is supported by more limited data
- Rapivab is not proven effective for serious influenza requiring hospitalization
- Rapivab does not treat bacterial infections, which can sometimes occur alongside or after the flu
⚙️How it works▾
Peramivir is a neuraminidase inhibitor. Neuraminidase is an enzyme on the surface of the influenza virus that helps newly formed virus particles escape from infected cells and infect new ones. Peramivir binds to and blocks this enzyme, limiting the virus's ability to spread through the body and helping to shorten the illness.
Because influenza viruses can change over time, some strains may develop resistance to peramivir, which could reduce how well it works. Your doctor will consider local flu strains and resistance patterns when deciding whether Rapivab is right for you.
💊How it's taken▾
Rapivab is given as a single one-time intravenous (IV) infusion — directly into a vein — over 15 to 30 minutes in a healthcare setting. It is not taken by mouth or self-administered at home. It must be given within 2 days of when flu symptoms start.
- Given as a single dose — not a multi-day course
- Patients with reduced kidney function require a lower dose; those on hemodialysis should receive it after their session
- Follow your prescriber's and healthcare team's instructions exactly for timing and preparation
🤒Side effects — in detail▾
Most people tolerate Rapivab well after a single dose. The most commonly reported side effect is diarrhea.
- Diarrhea
- Elevated blood sugar levels (detected on lab tests)
- Elevated liver enzyme levels (detected on lab tests)
- Elevated creatine phosphokinase — an enzyme that reflects muscle activity — levels (detected on lab tests)
- Low neutrophil count (a type of infection-fighting white blood cell)
Seek emergency care immediately if you experience signs of a severe allergic reaction (throat tightening, severe rash, difficulty breathing) or a serious skin reaction such as blistering or peeling — these are rare but require urgent treatment.
⚠️Warnings & precautions▾
- Severe allergic reactions: Rare but serious reactions — including anaphylaxis, Stevens-Johnson syndrome (severe skin blistering), and erythema multiforme — have been reported. Rapivab must be stopped immediately if any of these occur.
- Neuropsychiatric events: Flu itself can cause sudden hallucinations, confusion, or abnormal behavior, especially in children. These have also been reported in people receiving neuraminidase inhibitors like Rapivab. Watch closely for any sudden changes in behavior and get medical help right away.
- Bacterial infections: Rapivab only works against the influenza virus. It will not prevent or treat bacterial complications of the flu. If symptoms worsen or a new high fever develops, tell your doctor promptly.
- Kidney impairment: People with reduced kidney function need dose adjustments to avoid drug buildup.
🔀What it interacts with▾
Rapivab has one key drug interaction to be aware of:
- Live attenuated influenza vaccine (LAIV) — nasal spray flu vaccine: Avoid this vaccine within 2 weeks before or 48 hours after receiving Rapivab. Peramivir may interfere with the live virus in the vaccine, reducing how well the vaccine works. The standard inactivated flu shot is not affected and can be given at any time relative to Rapivab.
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Severe allergy to peramivir: Rapivab is contraindicated — meaning it must not be used — in anyone with a known serious allergic reaction to peramivir or any ingredient in Rapivab.
- Kidney disease or dialysis: Dose adjustment is required. Patients on hemodialysis should receive Rapivab after their dialysis session.
- Pregnancy: Data in pregnant people are very limited. Pregnant individuals are at higher risk of serious flu complications. Animal studies at high doses showed some fetal effects. Discuss the risks and benefits with your doctor.
- Breastfeeding: It is unknown whether peramivir passes into human breast milk. The benefit of treatment should be weighed against any potential risk to the infant.
- Children under 6 months: Safety and effectiveness have not been established in this age group.
- Children 6 months to under 2 years with kidney problems: There is not enough data to recommend a dose adjustment in this specific group — consult your doctor.
🚑If you take too much▾
There is no reported experience of Rapivab overdose in humans. If an overdose is suspected, treatment focuses on supportive care — monitoring vital signs and the patient's overall clinical condition. There is no specific antidote. Because peramivir is cleared through the kidneys, hemodialysis can help remove it from the body.
📡Pharmacodynamics — effects in the body▾
At twice the maximum recommended dose, Rapivab did not cause any clinically meaningful prolongation of the QTc interval — a measure of the heart's electrical activity — meaning it is not expected to cause heart rhythm problems at standard doses.
🔬Pharmacokinetics — how your body processes it▾
After a single IV infusion of Rapivab, drug levels in the blood rise quickly and peak at the end of the infusion. The amount of drug in the body increases proportionally with the dose. Peramivir binds minimally to proteins in the blood. It is cleared primarily through the kidneys, which is why people with reduced kidney function need lower doses to avoid drug accumulation.
📦How to store it▾
Store vials of RAPIVAB injection in original cartons at 20°C to 25°C (68°F to 77°F).
📄 Written from Peramivir Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Peramivir Injection — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly does Rapivab do, and how is it different from other flu treatments? ▾
Will I need more than one dose? ▾
What side effects should I watch for after receiving it? ▾
I've heard the flu can sometimes cause confusion or odd behavior — is that from Rapivab or the flu itself? ▾
Is it safe if I'm pregnant or breastfeeding? ▾
Can I still get my flu shot if I've received Rapivab? ▾
Is Peramivir Injection available over the counter? ▾
When was Peramivir Injection first available? ▾
💬 Answers drafted from Peramivir Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Peramivir Injection comes
Peramivir Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Rapivab is used to treat acute uncomplicated influenza in patients 6 months of age and older
- Rapivab must be started within 2 days of the onset of flu symptoms
- Rapivab's effectiveness is primarily established for influenza A; fewer influenza B patients were studied
- Rapivab has not been shown to be effective for serious influenza requiring hospitalization
- Rapivab is given as a single intravenous infusion over 15 to 30 minutes by a healthcare provider
- Rapivab must be diluted before administration; do not mix or co-infuse with other IV medications
- Rapivab dose is adjusted for patients with reduced kidney function; those on hemodialysis should receive it after dialysis
- Once diluted, Rapivab should be used immediately or refrigerated and used within 24 hours
📊 Peramivir Injection across the U.S. market
How Peramivir Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
🔍 Compare Peramivir Injection products
A representative set of FDA-listed product records for Peramivir Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 600 mg/60 mL | Intravenous | BioCryst Pharmaceuticals, Inc. × 2 listings | NDA | View NDC → |
Showing 2 of 2 products — FDA National Drug Code Directory. See every product, package size and price: browse all 2 Peramivir Injection NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Peramivir Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Peramivir Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Peramivir Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 619693 1 dose form · 1 strength
-
Dose form (SCDF) Injection RxCUI 1724184In current FDA listingsClinical drug / strength (SCD) 20 ML peramivir 10 MG/MLRxCUI 1598082
Look up RxCUI 619693 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Peramivir Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Peramivir Injection belongs to the Neuraminidase inhibitors class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 1 FDA-filed SPL label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. BioCryst Pharmaceuticals, Inc. is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.